Patients with Congenital Myasthenic Syndrome will be treated with Mesenchymal Stem Cell Exosome solution.

Single Arm non-controlled study. Patients are prospectively evaluated then treated. Outcomes are tracked after treatment.

Inclusion Criteria:

• Patients will need a diagnosis of Congenital Myasthenic Syndrome by a licensed physician.
• Patients must be able to provide informed consent, or have a guardian who does.
• Patient must be able to travel to the site of treatment.

Exclusion Criteria:

• Patients will be excluded from the trial if they are pregnant or have active cancer (malignancy) at the screening consultation.